Latest news with #LotteBiologics
![[Bio USA] Lotte heir deepens global biotech outreach at Bio USA](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F17%2Fnews-p.v1.20250617.5d83ef2cc2dc48378e5a284a0e7e1c62_T1.jpg&w=3840&q=100)
![[Bio USA] Lotte heir deepens global biotech outreach at Bio USA](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75){kind=small}
Korea Herald
2 days ago
- Business
- Korea Herald
[Bio USA] Lotte heir deepens global biotech outreach at Bio USA
BOSTON -- Shin Yoo-yeol, head of global strategy at Lotte Biologics and the eldest son of Lotte Group Chairman Shin Dong-bin, was seen engaging with industry players at the 2025 BIO International Convention in Boston on Monday. While most of the practical discussions at exhibitor booths were led by Lotte Biologics CEO James Park, who accompanied the younger Shin throughout the event, Shin was seen listening attentively to key business updates, exchanging business cards with booth representatives and showing genuine interest in the conversations. 'This is my second time attending the Bio USA, and I have high expectations for this year," Shin told reporters at the venue. 'I plan to attend several key meetings with global companies throughout the period.' Shin's booth tour included Korean and international names, such as Dong-A ST, Celltrion, Dr. Reddy's Biologics, Thermo Fisher Scientific and SK Pharmteco, reflecting his broad interest in potential partners and future collaboration. 'While there's a predetermined list of booths to visit, Shin also adds companies he finds interesting on the spot,' said a Lotte Biologics official. At the Dong-A ST booth, with Shin present, ST Pharm CEO Sung Moo-jae and Lotte Biologics CEO exchanged questions regarding antibody-drug conjugate (ADC) development, and discussed the potential for future business cooperation. Earlier this year in January, Shin made an appearance at the JPMorgan Healthcare Conference in San Francisco, where other second- and third-generation conglomerate leaders, including Celltrion's Seo Jin-seok and SK Biopharmaceuticals' Chey Yoon-chung also attended. At the time, Shin's participation followed a visit to CES 2025 in Las Vegas. This time, he is believed to have arrived at Bio USA after participating in the 2025 Consumer Goods Forum Global Summit, held June 10–13 in Amsterdam, Netherlands.
Korea Herald
24-04-2025
- Business
- Korea Herald
Lotte Biologics kicks off ADC service at Syracuse plant
Lotte Biologics announced on Thursday that it has signed a manufacturing deal with a biotech firm based in Asia to produce a clinical-stage antibody-drug conjugate candidate. The deal represents the first major milestone in launching full-scale operations at the company's ADC manufacturing facility, located at the Syracuse Bio Campus in the US state of New York, an expansion project that began in 2023. Through the contract, Lotte Biologics is officially introducing its ADC contract development and manufacturing services, tailored to support clients across all stages, from clinical trials to commercial-scale production. "With this contract as a starting point, we will ensure a stable supply of high-quality ADC therapeutics and solidify our position in the global market, not only as an antibody manufacturer, but also as a CDMO specializing in ADCs,' Lotte Biologics CEO James Park said. 'We also plan to actively pursue partnerships to further strengthen our competitiveness in the ADC modality business." Lotte Biologics will continue to seek new clients and expand its collaborative efforts, aiming to provide integrated, one-stop solutions for ADC development and production, the firm said. Developed with an investment of around $100 million, Lotte Biologics' ADC facility meets the current Good Manufacturing Practices of the US Food and Drug Administration and delivers comprehensive end-to-end manufacturing services. The facility includes a fully integrated production and purification system, featuring a conjugation reactor capable of handling up to 1,000 liters. It also offers in-house quality control testing and advanced analytical characterization services. Additionally, the site is outfitted with a single-use system that supports the entire workflow — from antibody preprocessing to the automated aseptic filling of drug substances — allowing for flexible and efficient service tailored to diverse client requirements.
